COMMUNIQUÉS West-GlobeNewswire

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
07/01/2026
BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
07/01/2026
U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter of 2026 On [...]
Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism
07/01/2026
Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications Company plans to meet with FDA to align on path forward for congenital HI [...]
Avance Clinical Strengthens Global Oncology Offering with Acquisition of U.S.-Based LumaBridge and Establishes New Oncology Center of Excellence
07/01/2026
ADELAIDE, Australia, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, a global contract research organization focused on accelerating clinical development for biotech sponsors, today announced the acquisition of [...]
Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance
07/01/2026
2026 Guidance Represents Year-Over-Year Increase of 13% in Revenues and 23% in Adjusted EBITDA Based on Mid-Point of 2025 Annual Guidance 2026 Annual Guidance is Based Solely on Continued Organic Growth Company [...]
Curium’s Investigational New Drug Application Accepted by Center for Drug Evaluation in China
07/01/2026
Curium’s Investigational New Drug (IND) application for 177 Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer (mCRPC), has been accepted by the Centre for Drug [...]
RadNet Expands to Southwest Florida with Acquisition of Radiology Regional
07/01/2026
Purchase of 13 imaging centers brings cutting-edge diagnostic technology to one of Florida’s fastest-growing regions. LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in [...]
ExamWorks Announces Strategic Leadership Transition Plan to Further Accelerate Long-Term Growth
07/01/2026
ATLANTA, GA, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ExamWorks Group (“ExamWorks”), a leading global provider of medical claims management solutions, including independent medical examinations, peer reviews, record retrieval [...]
RadNet Names Four Leaders to Expanded Executive Roles
07/01/2026
Bench of veteran leaders elevated to drive RadNet’s continued growth and innovation LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective [...]
Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical
07/01/2026
Amsterdam, the Netherlands, January 7, 2026 – Scenic Biotech , a pioneer in the field of modifier therapies for severe diseases, today announced a license and research agreement with Ono Pharmaceutical Co., Ltd. to [...]
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies
07/01/2026
Collaboration with Amgen to advance a cancer target discovered using DISCO’s proprietary surfaceome mapping technology Cologne, Germany, January 7, 2026 – DISCO Pharmaceuticals (“DISCO”), today announced an exclusive [...]
Is MEDVi a Trusted GLP-1 Supplier for 2026? What to Know Before Choosing a Telehealth Weight Loss Platform
07/01/2026
New York City, NY, Jan. 07, 2026 (GLOBE NEWSWIRE) -- As demand for GLP-1 weight loss medications continues to rise in 2026, many consumers are actively searching for a reliable GLP-1 supplier that offers affordability, [...]
Correction: JJP Biologics Announces Positive Top-Line Phase I Trial Results of JJP-1212, its anti-CD89 antagonist
07/01/2026
Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the program Supports the feasibility of intravenous and subcutaneous dosing regimens in upcoming clinical [...]
World-renowned Immunologist and Distinguished Scientist Joins CancerVax as Senior Scientific Advisor
07/01/2026
Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on immunological strategies for its novel cancer treatment platform Lehi Utah, Jan. 07, 2026 (GLOBE NEWSWIRE [...]
Relation Announces Strategic Collaboration with Deerfield Management to Advance Novel Therapeutics
07/01/2026
LONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Relation and healthcare investment firm Deerfield Management, a current investor, today announced the establishment of a new research collaboration to advance therapeutic [...]
Bavarian Nordic Launches Planned Share Buy-Back Program
07/01/2026
COPENHAGEN, Denmark, January 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the first tranche of the share buy-back program announced on December 2, 2025 , under which the Company intends to repurchase own [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
07/01/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 7 January 2026 at 08.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections
07/01/2026
Allschwil, Switzerland, January 07, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]
JJP Biologics Announces Positive Top-Line Phase I Trial Results of JJP-1212, its anti-CD89 antagonist
07/01/2026
Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the program Supports the feasibility of intravenous and subcutaneous dosing regimens in upcoming clinical [...]

Pages